Kyntra Bio (KYNB) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to 502.88%.
- Kyntra Bio's EBIT Margin rose 382711000.0% to 502.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 262.36%, marking a year-over-year decrease of 729800.0%. This contributed to the annual value of 2089.11% for FY2024, which is 13995800.0% down from last year.
- Kyntra Bio's EBIT Margin amounted to 502.88% in Q3 2025, which was up 382711000.0% from 894.07% recorded in Q2 2025.
- In the past 5 years, Kyntra Bio's EBIT Margin ranged from a high of 128.84% in Q4 2023 and a low of 38773.98% during Q3 2024
- Its 5-year average for EBIT Margin is 3405.52%, with a median of 611.44% in 2023.
- As far as peak fluctuations go, Kyntra Bio's EBIT Margin tumbled by -386158100bps in 2024, and later surged by 382711000bps in 2025.
- Kyntra Bio's EBIT Margin (Quarter) stood at 817.51% in 2021, then skyrocketed by 76bps to 192.49% in 2022, then skyrocketed by 167bps to 128.84% in 2023, then crashed by -71bps to 36.99% in 2024, then crashed by -1460bps to 502.88% in 2025.
- Its last three reported values are 502.88% in Q3 2025, 894.07% for Q2 2025, and 828.89% during Q1 2025.